Valeant, Biovail Settle Class Action Over $3B Merger
Valeant Pharmaceuticals International and Biovail Corp. have settled a shareholder class action that sought to block their $3.2 billion merger....To view the full article, register now.
Already a subscriber? Click here to view full article